Tonix Pharmaceuticals

The US Food and Drug Administration (FDA) is actively engaging with pharmaceutical companies to address an impending shortage of a critical migraine treatment. This follows the UK-based GlaxoSmithKline’s (GSK; NYSE: GSK) decision to discontinue the production of Imitrex (sumatriptan) nasal spray from January 31, 2024. The move has prompted concerns…